Tevogen Inc. Common Stock (TVGN) Stock Price

TVGNStock
$7.07−81.27%52W
Market Cap$46.04M
P/E—
PEG Ratio—
Div yield—
Beta0.27

TVGN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)16.80%
Price vs S&P 500 (4W)-8.15%
VGM Score66.81

TVGN Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q4 2025-$1.50-$7.96-430.67%(-$6.46)
Q3 2025-$3.00-$1.50+50.00%(+$1.50)
Q2 2025-$2.50-$1.50+40.00%(+$1.00)
Q1 2025-$2.50-$3.50-40.00%(-$1.00)

TVGN Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
2.17
2.17
2.17
2.17

Industry Peers — Biological Products(186)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
TVGNTevogen Inc. Common Stock
——B————$7.07
AMGNAmgen IncDCA6.1x9.1%74.3%2.9%$432.49
GILDGilead Sciences IncCBA6.4x5.5%79.6%133.6%$156.19
MRNAModerna, Inc. Common StockFCA39.1x-27.6%36.4%—$218.01
ARGXargenx SE American Depositary SharesDAB6.6x165.2%89.8%—$819.14
RVMDRevolution Medicines, Inc. Common StockF—B3296.2x———$177.96
BIIBBiogen Inc. Common StockCDA3.4x0.3%74.0%-18.8%$232.65
BNTXBioNTech SE American Depositary ShareCCC7.6x-11.8%79.2%—$87.71
EXELExelixis IncCBA6.3x9.2%96.5%31.1%$62.23
HALOHalozyme Therapeutics, Inc.DBA8.3x41.1%82.4%22.9%$121.84
NBIXNeurocrine Biosciences IncCBB4.1x34.4%98.0%2.3%$135.71

About Tevogen Inc. Common Stock

Tevogen Bio Holdings is a clinical-stage immunotherapy company developing off-the-shelf T cell therapies. The company harnesses CD8+ cytotoxic T lymphocytes to create precision treatments for infectious diseases, cancers, and neurological disorders. Its platform is designed for broad use without requiring patient-specific customization.